B2M and head and neck squamous cell carcinoma: In head-and-neck squamous cell carcinoma (HNSCC), GSK126 or EPZ-6438 (tazemetostat) reduced H3K27me3 occupancy at the B2M promoter, upregulated MHC-I enhanced antigen-specific CD8+ T-cell proliferation/IFN-γ, and sensitized anti-PD-1-resistant tumors to checkpoint blockade in mice [123].